T-cell immunotherapy: Catching Up to the User Requirements

Sean Kevlahan, CEO and Co-Founder, Quad Therapeutics

Video Overview

Sean Kevlahan founded Quad Technologies to address key challenges in the production process for CAR-T cells, a class of immunotherapeutics showing remarkable promise in the field of oncology. In his presentation Dr. Kevlahan discusses the decision-making process Quad employed to derive the requirements for their initial products, QuickGel and MagCloudz, as well as reviewing the remaining technical bottlenecks that Quad intends to tackle over the coming years.